4 recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 4 |
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1104 | 2026-09-25 | 2026-10-23 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-08-27 | 2026-10-23 |
| A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO Tabirafusp tedromer, Aflibercept (2.0 mg) - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Kodiak Sciences Inc | 910 | 2026-08-03 | 2026-08-21 |
| A Study to Compare GNR-139 and Eylea® in Patients With nAMD aflibercept, Eylea - nAMD | Phase 3 | Recruiting | AO GENERIUM | 180 | 2026-07-22 | 2026-09-30 |
Diabetic Retinopathy (2) · Macular Edema (2)
Merck Sharp & Dohme LLC (2) · AO GENERIUM (1) · Kodiak Sciences Inc (1)
United States (3) · Argentina (1) · Australia (1) · Russia (1) · United Kingdom (1)